Suchergebnisse - "Subramaniam, Deepa"

Recasting of Periodontal Diagnosis.

Autoren: Subramaniam, Deepa Swamikannu, Bhumimathan Raghavan, R. Narasimha et al.

Quelle: Journal of Pharmacy & Bioallied Sciences; 2025 Suppl 3, Vol. 17, pS2060-S2066, 7p

Schlagwörter: PERIODONTAL disease, DIAGNOSIS, ACQUISITION of data, INTERDISCIPLINARY research, ARTIFICIAL intelligence, TECHNOLOGICAL innovations, CLASSIFICATION, MOLECULAR diagnosis

Biphasic Calcium Phosphate in the Extraction Socket Preservation: A Systematic Review.

Autoren: S., Mohanasatheesh Balaji, Anitha Subramaniam, Deepa et al.

Quelle: Journal of Pharmacy & Bioallied Sciences; 2024 Supplement, Vol. 16, pS1007-S1011, 5p

Schlagwörter: CALCIUM phosphate, BONE regeneration, DENTAL extraction, DENTAL materials, BONE substitutes

People: OVID, 43 B.C.-17 or 18 A.D.

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.

Autoren: Reardon, David A. Kim, Tae Min Frenel, Jean‐Sebastien et al.

Quelle: Cancer (0008543X); May2021, Vol. 127 Issue 10, p1620-1629, 10p

Schlagwörter: GLIOBLASTOMA multiforme, BRAIN tumors, GENE expression profiling, PEMBROLIZUMAB, ADVERSE health care events, STEROID drugs

Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control.

Autoren: Taylor, Kathryn L. Fallon, Shelby Subramaniam, Deepa et al.

Quelle: Journal of Cancer Survivorship; Feb2020, Vol. 14 Issue 1, p53-58, 6p

Clinical Activity of Nivolumab for Human Papilloma Virus‐Related Juvenile‐Onset Recurrent Respiratory Papillomatosis.

Autoren: Creelan, Ben C. Ahmad, M. Usman Kaszuba, Frank J. et al.

Quelle: Oncologist; Jun2019, Vol. 24 Issue 6, p829-835, 7p, 3 Color Photographs, 1 Diagram

Schlagwörter: AGE factors in disease, BIOPSY, CANCER patients, CANCER relapse, EPITHELIAL cells, IMMUNOHISTOCHEMISTRY, LARYNGOSCOPY, GENETIC mutation, PAPILLOMA, PAPILLOMAVIRUS diseases, RESPIRATORY organ tumors, T cells, VIRAL load, TREATMENT effectiveness, GENE expression profiling, DISEASE complications

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Autoren: Kim, Chul Liu, Stephen V. Crawford, Jennifer et al.

Quelle: Frontiers in Oncology; 9/8/2021, Vol. 12, p1-9, 9p

Schlagwörter: DASATINIB, NON-small-cell lung carcinoma, PROTEIN-tyrosine kinase inhibitors, OSIMERTINIB, ADVERSE health care events, EPIDERMAL growth factor receptors

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.

Autoren: Trivedi, Neel D. Armstrong, Samantha Wang, Hongkun et al.

Quelle: Cancer Medicine; Mar2021, Vol. 10 Issue 6, p1944-1954, 11p

Schlagwörter: MTOR inhibitors, DRUG efficacy, COLORECTAL cancer, PREVENTIVE medicine, MUCOSITIS

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.

Autoren: Kong, Amanda M. Pavilack, Melissa Huo, Hairong et al.

Quelle: Journal of Medical Economics; Jan-Dec 2021, Vol. 24 Issue 1, p328-338, 11p

Schlagwörter: BRAIN metastasis, MEDICAL care use, NON-small-cell lung carcinoma, EPIDERMAL growth factor receptors, MEDICAL care costs

Geografische Kategorien: UNITED States

Volume 24 Author Index.

Quelle: Oncologist; Dec2019, Vol. 24 Issue 12, pe1496-e1518, 23p

RARE-05. TUMOR PROFILING REVEALS EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AND ENHANCED IMMUNE SUPPRESSION IN GLIOSARCOMAS RELATIVE TO GLIOBLASTOMA.

Autoren: Dardis, Christopher Phuphanich, Surasak Sanai, Nader et al.

Quelle: Neuro-Oncology; 2018 Supplement, Vol. 20, pvi237-vi237, 1p

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Autoren: Lynce, Filipa Wang, Hongkun Petricoin, Emanuel F. et al.

Quelle: Cancer Chemotherapy & Pharmacology; Nov2019, Vol. 84 Issue 5, p1145-1151, 7p

Schlagwörter: BORTEZOMIB, PROTEASOME inhibitors, KINASE inhibitors, LAPATINIB, PROTEASOMES, ADVERSE health care events

ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS.

Autoren: Reardon, David Kaley, Thomas Iwamoto, Fabio et al.

Quelle: Neuro-Oncology; 2018 Supplement, Vol. 20, pvi6-vi6, 1p

Comparative Evaluation of Subgingivally Delivered Tetracycline Fibers and Aloe Vera Gel as an Adjunct to Scaling and Root Planing in Treatment of Chronic Periodontitis: A Randomized Controlled Clinical Trial.

Autoren: Thakuria, Anurag Agarwal, Swati Madan, Ellora et al.

Quelle: Journal of Pharmacy & Bioallied Sciences; 2024 Suppl, Vol. 16, pS3206-S3208, 3p

Schlagwörter: SALINE irrigation, PERIODONTAL pockets, CLINICAL trials, ALOE vera, RANDOMIZED controlled trials, TETRACYCLINE

Surgical Excision of Hypertrophic Tissue and Retrieval of Orthodontic Mini-implant using Diode Laser-A Rare Case Report.

Autoren: IDA, EVANGELINE RAMYA, V. BALAJI, ANITHA et al.

Quelle: Journal of Clinical & Diagnostic Research; Aug2023, Vol. 17 Issue 8, p1-3, 3p

Thanks to Authors and Peer Reviewers.

Quelle: Cancer (0008543X); Dec2015, Vol. 121 Issue 24, p4447-4456, 35p

Schlagwörter: CANCER periodicals

People: FISHER, Jay, ALIBHAI, Shabbir

¹¹C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.

Autoren: Kreisl, William C. Lawrence, Robin Page, Emily et al.

Quelle: Neurology; 3/7/2017, Vol. 88 Issue 10, p1001-1004, 4p

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Autoren: Crandall, John Tahari, Abdel Juergens, Rosalyn et al.

Quelle: EJNMMI Research; 1/19/2017, Vol. 7 Issue 1, p1-10, 10p

Schlagwörter: CANCER treatment, NON-small-cell lung carcinoma, CANCER chemotherapy, COMPUTED tomography, POSITRON emission tomography, FLUORODEOXYGLUCOSE F18, TUMOR classification

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

Autoren: Wakelee, Heather Gettinger, Scott Engelman, Jeffrey et al.

Quelle: Cancer Chemotherapy & Pharmacology; May2017, Vol. 79 Issue 5, p923-932, 10p

Schlagwörter: CANCER treatment, NON-small-cell lung carcinoma, ERLOTINIB, KINASE inhibitors, COMBINATION drug therapy, CANCER invasiveness, GENETIC mutation, CLINICAL trials, THERAPEUTICS

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk.

Autoren: Repka, Michael C. Lei, Siyuan Campbell, Lloyd et al.

Quelle: Frontiers in Oncology; 9/11/2018, pN.PAG-N.PAG, 7p

Schlagwörter: GLIOMA treatment, STEREOTACTIC radiotherapy, FOLLOW-up studies (Medicine)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Autoren: Kelly, William J. Shah, Neil J. Subramaniam, Deepa S.

Quelle: Frontiers in Oncology; 7/3/2018, pN.PAG-N.PAG, 9p

Schlagwörter: SMALL cell lung cancer, EPIDERMAL growth factor receptors